Literature DB >> 30295334

Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident.

Larysa Poluben1,2, Maneka Puligandla3, Donna Neuberg3, Christine R Bryke4, Yahsuan Hsu4, Oleksandr Shumeiko2, Xin Yuan1, Olga Voznesensky1, German Pihan4, Miriam Adam5, Ernest Fraenkel5, Roni Rasnic6, Michal Linial6, Sergiy Klymenko2, Steven P Balk1, Paula G Fraenkel1.   

Abstract

Myeloproliferative neoplasms (MPNs) driver mutations are usually found in JAK2, MPL, and CALR genes; however, 10%-15% of cases are triple negative (TN). A previous study showed lower rate of JAK2 V617F in primary myelofibrosis patients exposed to low doses of ionizing radiation (IR) from Chernobyl accident. To examine distinct driver mutations, we enrolled 281 Ukrainian IR-exposed and unexposed MPN patients. Genomic DNA was obtained from peripheral blood leukocytes. JAK2 V617F, MPL W515, types 1- and 2-like CALR mutations were identified by Sanger Sequencing and real time polymerase chain reaction. Chromosomal alterations were assessed by oligo-SNP microarray platform. Additional genetic variants were identified by whole exome and targeted sequencing. Statistical significance was evaluated by Fisher's exact test and Wilcoxon's rank sum test (R, version 3.4.2). IR-exposed MPN patients exhibited a different genetic profile vs unexposed: lower rate of JAK2 V617F (58.4% vs 75.4%, P = .0077), higher rate of type 1-like CALR mutation (12.2% vs 3.1%, P = .0056), higher rate of TN cases (27.8% vs 16.2%, P = .0366), higher rate of potentially pathogenic sequence variants (mean numbers: 4.8 vs 3.1, P = .0242). Furthermore, we identified several potential drivers specific to IR-exposed TN MPN patients: ATM p.S1691R with copy-neutral loss of heterozygosity at 11q; EZH2 p.D659G at 7q and SUZ12 p.V71 M at 17q with copy number loss. Thus, IR-exposed MPN patients represent a group with distinct genomic characteristics worthy of further study.
© 2018 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30295334      PMCID: PMC6371805          DOI: 10.1002/ajh.25307

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  64 in total

1.  [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Authors:  János László Iványi; Eva Marton; Márk Plander
Journal:  Orv Hetil       Date:  2011-11-06       Impact factor: 0.540

Review 2.  SF3B1 mutations in chronic lymphocytic leukemia.

Authors:  Youzhong Wan; Catherine J Wu
Journal:  Blood       Date:  2013-04-08       Impact factor: 22.113

3.  Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.

Authors:  Joannah Score; Claire Hidalgo-Curtis; Amy V Jones; Nils Winkelmann; Alison Skinner; Daniel Ward; Katerina Zoi; Thomas Ernst; Frank Stegelmann; Konstanze Döhner; Andrew Chase; Nicholas C P Cross
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

4.  Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis.

Authors:  Hao Kong; Yancheng Liu; Sai Luo; Qiaoqiao Li; Qinglu Wang
Journal:  Intern Med       Date:  2016-08-01       Impact factor: 1.271

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.

Authors:  A Pardanani; T L Lasho; R R Laborde; M Elliott; C A Hanson; R A Knudson; R P Ketterling; J E Maxson; J W Tyner; A Tefferi
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

7.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

8.  Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.

Authors:  Debanjali Mitra; James A Kaye; Lance T Piecoro; Jennifer Brown; Kelly Reith; Tariq I Mughal; Nicholas J Sarlis
Journal:  Cancer Med       Date:  2013-10-05       Impact factor: 4.452

9.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

10.  Low frequency of c-MPL gene mutations in Iranian patients with Philadelphia-negative myeloproliferative disorders.

Authors:  A Ghotaslou; F Nadali; B Chahardouli; N Alizad Ghandforosh; S H Rostami; K Alimoghaddam; A Ghavamzadeh
Journal:  Iran J Ped Hematol Oncol       Date:  2015-03-15
View more
  3 in total

Review 1.  Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.

Authors:  Laura F Mendez Luque; Amanda L Blackmon; Gajalakshmi Ramanathan; Angela G Fleischman
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

Review 2.  Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN.

Authors:  Gajalakshmi Ramanathan; Brianna M Hoover; Angela G Fleischman
Journal:  Cancers (Basel)       Date:  2020-07-24       Impact factor: 6.575

Review 3.  Extramedullary Hematopoiesis of the Liver and Spleen.

Authors:  Diana Cenariu; Sabina Iluta; Alina-Andreea Zimta; Bobe Petrushev; Liren Qian; Noemi Dirzu; Ciprian Tomuleasa; Horia Bumbea; Florin Zaharie
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.